The US Food and Drug Administration (FDA) has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a ...

THE United States Food and Drug Administration (FDA) on Wednesday approved Gilead Sciences' lenacapavir, a drug to be injected twice annually, for preventing HIV infection in adults and adolescents at ...

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

FDA approves Yeztugo HIV prevention injection showing 96% efficacy in clinical trials, but $14,000 cost creates significant access barriers for patients.

In two recent studies, this new shot reportedly nearly eliminated new infections in people at substantial risk of HIV.

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

The 2025 Warren Alpert Foundation Prize has been awarded to three scientists whose discoveries culminated in the development ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it’s unclear how many in the ...

Newly FDA-approved HIV prevention drug, Yeztugo, offers protection for six months—yet the need for a vaccine remains, say ...